NICE National Institute for Health and Care Excellence

Single Technology Appraisal

Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane

Evaluation Report

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

SINGLE TECHNOLOGY APPRAISAL

Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane

Contents:

1. **Pre-Meeting Briefing**

2. **Manufacturer/sponsor submission** from Roche Products

3. **Clarification letters**
   - NICE request to the manufacturer for clarification on their submission
   - Manufacturer's response to NICE's request for clarification

4. **Patient group, professional group and NHS organisation submission** from:
   - Breakthrough Breast cancer
   - Breast Cancer Care
   - Royal College of Nursing
   - Royal College of Physicians (NCRI Breast Cancer CSG/RCR/ACP/JCCO)

5. **Expert personal perspectives** from:
   - Dr Gianfilippo Bertelli, Clinical expert, nominated by Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO)
   - Dr Anne Armstrong, Clinical Expert, nominated by Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO)
   - Tara Beaumont, Patient expert, nominated by Breast Cancer Care
   - Elizabeth Segal, Patient expert, nominated by Breakthrough Breast Cancer Care

6. **Evidence Review Group report** prepared by School of Health and Related Research (ScHARR), The University of Sheffield

7. **Evidence Review Group report – factual accuracy check**

8. **Evidence Review Group report – replacement pages**

Any information supplied to NICE which has been marked as confidential, has been redacted. All personal information has also been redacted.